GBT Granted Rights to SCD Small Molecule Programs in Deal With Sanofi

GBT Granted Rights to SCD Small Molecule Programs in Deal With Sanofi

291243

GBT Granted Rights to SCD Small Molecule Programs in Deal With Sanofi

Global Blood Therapeutics (GBT) has been granted exclusive global rights to two small-molecule research programs for sickle cell disease (SCD) as part of a newly announced agreement between GBT and Sanofi. The two early stage programs, from Sanofi’s subsidiary Bioverativ, will explore new mechanisms to prevent or reverse red blood cell sickling. They aim to develop a new therapeutic approach to reduce inflammation and oxidative stress, both of which contribute to the damaging effects of SCD.…

You must be logged in to read/download the full post.